Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.
A Nested Phase 3, Randomized, Active-controlled, Open-label, 2-arm, Multicenter Study to Investigate the Immunogenicity and Safety of Sanofi's Hexavalent DTaP-IPV-HB-PRP~T Combined Vaccine Given at 2, 4, and 6 Months of Age Compared With DTaP-IPV//PRP~T Combined Vaccine (Pentaxim™) Given at 2, 4, and 6 Months of Age Administered With a Monovalent Hepatitis B Vaccine Given at 1 and 6 Months of Age to Healthy Chinese Infants Who Previously Received a Birth Dose of Monovalent Hepatitis B Vaccine
The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers.
Study details include:
- The study duration per participant will be approximately 18 months.
- The study vaccines administration:
- Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA.
- Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4, and 6 MoA, and the monovalent Hep B vaccine will be administered at 1 and 6 MoA.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Trial Transparency email recommended (Toll free for US & Canada)
- Phone Number: option 6 800-633-1610
- Email: Contact-US@sanofi.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 30 to 45 days on the day of inclusion, and have received 1 dose of monovalent Hep B vaccine
- Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period above 28 (>28 weeks) through 36 weeks with a birth weight ≥1.5 kg, and in both cases medically stable as assessed by the investigator
- Participants who are born to mothers with documented HBsAg seronegative status
- Informed consent form has been signed and dated by the parent(s) or other LAR
- Participant and parent/LAR are able to attend all scheduled visits and to comply with all study procedures
Exclusion Criteria:
- Known/suspected immunodeficiency; immunosuppressive therapy since birth; long-term systemic corticosteroid therapy
- History of diagnosis of Hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection
- History of seizure or significant stable or progressive neurological disorders
- Known systemic hypersensitivity to any study intervention components, or history of a life-threatening reaction to study interventions or product with the same substances
- Known thrombocytopenia
- Bleeding disorder
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
- Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (axillary temperature ≥37.5°C) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
- Any vaccine given since birth or planned receipt of any vaccine until 1 month after the completion of the primary series vaccination with the study interventions except for Bacille Calmette-Guérin (BCG) vaccine and meningococcal polysaccharide vaccine-A.
- Previous vaccination against D, T, pertussis, poliomyelitis, Hep B (except the dose of Hep B given at birth) or Haemophilus influenzae type b infections (since birth) with an investigational or marketed vaccine.
- Receipt of immune globulins, blood or blood-derived products
- Participation in another clinical study for a vaccine, drug, medical device, or medical procedure at the time of study enrollment or planned participation during the present study period.
- Known personal or maternal history of HIV or HCV seropositivity
- Being in an emergency setting
- Identified as a natural or adopted child of the Investigator/study site employee with direct involvement in the study
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group 1 (the investigational group)
Hexaxim at 2, 4 and 6 MoA |
Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection |
|
Active Comparator: Group 2 (the comparator group)
Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA |
Pharmaceutical form:Freeze-dried PRP~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection Pharmaceutical form: Depending on the brand procured Route of administration:IM injection |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
Time Frame: Day181
|
Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA |
Day181
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Baseline, pre-vaccination sample
Time Frame: Day 31
|
Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off:
|
Day 31
|
|
1 month after the last dose of primary series:
Time Frame: Day181
|
Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off:
|
Day181
|
|
Before the booster dose:
Time Frame: Day 511
|
Ab concentrations/titers for each Ag of Pentaxim and Hep B Ab concentrations/titers above a cut-off:
|
Day 511
|
|
1 month after the booster dose:
Time Frame: Day 541
|
Ab concentrations/titers for each Ag of Pentaxim Ab concentrations/titers above a cut-off:
|
Day 541
|
|
Presence of immediate unsolicited adverse events (AEs)
Time Frame: 30 minutes after each and any vaccination
|
30 minutes after each and any vaccination
|
|
|
Presence of solicited injection site reactions
Time Frame: for 8 days, including the day of each and any vaccination
|
(pre-listed in the participant diary and case report form [CRF]) |
for 8 days, including the day of each and any vaccination
|
|
Presence of solicited systemic reactions
Time Frame: for 8 days, including the day of each and any vaccination
|
(pre-listed in the participant diary and CRF) |
for 8 days, including the day of each and any vaccination
|
|
Presence of unsolicited AEs
Time Frame: for 30 days, including the day of each and any vaccination
|
for 30 days, including the day of each and any vaccination
|
|
|
Presence of serious adverse events (SAEs)
Time Frame: up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
|
up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
|
|
|
Presence of related SAEs and fatal case regardless of causality
Time Frame: Day 541
|
Day 541
|
|
|
Presence of AEs leading to study discontinuation
Time Frame: Day 541
|
Day 541
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- A3L00054
- U1111-1227-3420 (Registry Identifier: ICTRP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.